Comprehensive Analysis of Prognosis and Immune Landscapes Based on Lipid-Metabolism- and Ferroptosis-Associated Signature in Uterine Corpus Endometrial Carcinoma

被引:6
作者
Yang, Pusheng [1 ]
Lu, Jiawei [2 ,3 ]
Zhang, Panpan [1 ]
Zhang, Shu [1 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Gynecol & Obstet,Shanghai Key Lab Gynecol Onc, Shanghai 200127, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Gastroenterol, Shanghai 201620, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Shanghai Key Lab Pancreat Dis, Shanghai 201620, Peoples R China
基金
中国国家自然科学基金;
关键词
lipid metabolism; ferroptosis; immunotherapy; prognostic marker; uterine corpus endometrial carcinoma; TUMOR MICROENVIRONMENT; CANCER-IMMUNOTHERAPY; CHECKPOINT BLOCKADE; GENE SIGNATURE; PREVENTION; BIOMARKERS; OBESITY; BURDEN;
D O I
10.3390/diagnostics13050870
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
(1) Background: The effect of tumor immunotherapy is influenced by the immune microenvironment, and it is unclear how lipid metabolism and ferroptosis regulate the immune microenvironment of uterine corpus endometrial carcinoma (UCEC). (2) Methods: Genes associated with lipid metabolism and ferroptosis (LMRGs-FARs) were extracted from the MSigDB and FerrDb databases, respectively. Five hundred and forty-four UCEC samples were obtained from the TCGA database. The risk prognostic signature was constructed by consensus clustering, univariate cox, and LASSO analyses. The accuracy of the risk modes was assessed through receiver operating characteristic (ROC) curve, nomogram, calibration,, and C-index analyses. The relationship between the risk signature and immune microenvironment was detected by the ESTIMATE, EPIC, TIMER, xCELL, quan-TIseq, and TCIA databases. The function of a potential gene, PSAT1, was measured by in vitro experiments. (3) Results: A six-gene (CDKN1A, ESR1, PGR, CDKN2A, PSAT1, and RSAD2) risk signature based on MRGs-FARs was constructed and evaluated with high accuracy in UCEC. The signature was identified as an independent prognostic parameter and it divided the samples into high- and low-risk groups. The low-risk group was positively associated with good prognosis, high mutational status, upregulated immune infiltration status, high expression of CTLA4, GZMA and PDCD1, anti-PD-1 treatment sensitivity, and chemoresistance. (4) Conclusions: We constructed a risk prognostic model based on both lipid metabolism and ferroptosis and evaluated the relationship between the risk score and tumor immune microenvironment in UCEC. Our study has provided new ideas and potential targets for UCEC individualized diagnosis and immunotherapy.
引用
收藏
页数:18
相关论文
共 58 条
[1]   Selenium Drives a Transcriptional Adaptive Program to Block Ferroptosis and Treat Stroke [J].
Alim, Ishraq ;
Caulfield, Joseph T. ;
Chen, Yingxin ;
Swarup, Vivek ;
Geschwind, Daniel H. ;
Ivanova, Elena ;
Seravalli, Javier ;
Ai, Youxi ;
Sensing, Lauren H. ;
Ste Marie, Emma J. ;
Hondal, Robert J. ;
Mukherjee, Sushmita ;
Cave, John W. ;
Sagdullaev, Botir T. ;
Karuppagounder, Saravanan S. ;
Ratan, Rajiv R. .
CELL, 2019, 177 (05) :1262-+
[2]   Endometrial cancer [J].
Amant, F ;
Moerman, P ;
Neven, P ;
Timmerman, D ;
Van Limbergen, E ;
Vergote, I .
LANCET, 2005, 366 (9484) :491-505
[3]   Estrogen-independent molecular actions of mutant estrogen receptor 1 in endometrial cancer [J].
Blanchard, Zannel ;
Vahrenkamp, Jeffery M. ;
Berrett, Kristofer C. ;
Arnesen, Spencer ;
Gertz, Jason .
GENOME RESEARCH, 2019, 29 (09) :1429-1441
[4]   Current recommendations and recent progress in endometrial cancer [J].
Brooks, Rebecca A. ;
Fleming, Gini F. ;
Lastra, Ricardo R. ;
Lee, Nita K. ;
Moroney, John W. ;
Son, Christina H. ;
Tatebe, Ken ;
Veneris, Jennifer L. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2019, 69 (04) :258-279
[5]   Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies [J].
Byun, David J. ;
Wolchok, Jedd D. ;
Rosenberg, Lynne M. ;
Girotra, Monica .
NATURE REVIEWS ENDOCRINOLOGY, 2017, 13 (04) :195-207
[6]   Immunotherapy in endometrial cancer: rationale, practice and perspectives [J].
Cao, Wenyu ;
Ma, Xinyue ;
Fischer, Jean Victoria ;
Sun, Chenggong ;
Kong, Beihua ;
Zhang, Qing .
BIOMARKER RESEARCH, 2021, 9 (01)
[7]   Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic [J].
Chan, T. A. ;
Yarchoan, M. ;
Jaffee, E. ;
Swanton, C. ;
Quezada, S. A. ;
Stenzinger, A. ;
Peters, S. .
ANNALS OF ONCOLOGY, 2019, 30 (01) :44-56
[8]   CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer [J].
Cheng, Tianyi ;
Wu, Yingyi ;
Liu, Zhiyu ;
Yu, Yi ;
Sun, Shixue ;
Guo, Min ;
Sun, Baoqing ;
Huang, Chen .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[9]   A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors [J].
Chida, Keigo ;
Kawazoe, Akihito ;
Kawazu, Masahito ;
Suzuki, Toshihiro ;
Nakamura, Yoshiaki ;
Nakatsura, Tetsuya ;
Kuwata, Takeshi ;
Ueno, Toshihide ;
Kuboki, Yasutoshi ;
Kotani, Daisuke ;
Kojima, Takashi ;
Taniguchi, Hiroya ;
Mano, Hiroyuki ;
Ikeda, Masafumi ;
Shitara, Kohei ;
Endo, Itaru ;
Yoshino, Takayuki .
CLINICAL CANCER RESEARCH, 2021, 27 (13) :3714-3724
[10]   ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway [J].
Chu, Bo ;
Kon, Ning ;
Chen, Delin ;
Li, Tongyuan ;
Liu, Tong ;
Jiang, Le ;
Song, Shujuan ;
Tavana, Omid ;
Gu, Wei .
NATURE CELL BIOLOGY, 2019, 21 (05) :579-+